A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE)
Sponsor: Novo Nordisk A/S
A PHASE3 clinical study on Diabetes and Diabetes Mellitus, Type 2, this trial is completed. The trial is conducted by Novo Nordisk A/S and has accumulated 15 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 10 earlier versions
-
Jul 2019 — Aug 2019 [monthly]
Completed PHASE3
-
Apr 2019 — Jul 2019 [monthly]
Completed PHASE3
-
Aug 2018 — Apr 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Dec 2017 — Feb 2018 [monthly]
Completed PHASE3
-
Jul 2017 — Dec 2017 [monthly]
Completed PHASE3
-
Mar 2017 — Jul 2017 [monthly]
Completed PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .